BACKGROUND: Approximately 10% of pancreatic ductal adenocarcinomas have a familial basis. While a small portion of this familial clustering can be explained by inherited mutations in known genes (BRCA2, p16/CDKN2A, PRSS1, and STK11), the genetic basis for the majority of this familial clustering remains unknown. In addition, a pancreatic cancer susceptibility locus has been reported to be linked to chromosome 4q32-34 in a single family having a high penetrance of early-onset pancreatic ductal adenocarcinoma and pancreatic insufficiency. The goal of this study is to determine if linkage to chromosome 4q exists in our series of well-characterized families with idiopathic familial pancreatic cancer enrolled in the Pancreatic Cancer Genetic Epidemiology Consortium (PACGENE). METHODS: Parametric and nonparametric linkage analyses were performed using 21 microsatellite markers on chromosome 4 on affected individuals with pancreatic cancer from 42 familial pancreatic cancer kindreds. RESULTS: Markov Chain Monte Carlo parametric and nonparametric linkage analyses using SIMWALK2 as well as nonparametric linkage analysis using MERLIN did not provide strong evidence of linkage in this region (LOD < 1.0). Only one family provided a multipoint LOD score of >0.5 adjacent to the reported region. CONCLUSIONS: Our results do not support linkage to the 4q32-34 region in the majority of our familial pancreatic cancer kindreds. However, because multiple pancreatic cancer susceptibility genes are likely to exist, it is possible that a subset of the families in this study may be linked to this region.
BACKGROUND: Approximately 10% of pancreatic ductal adenocarcinomas have a familial basis. While a small portion of this familial clustering can be explained by inherited mutations in known genes (BRCA2, p16/CDKN2A, PRSS1, and STK11), the genetic basis for the majority of this familial clustering remains unknown. In addition, a pancreatic cancer susceptibility locus has been reported to be linked to chromosome 4q32-34 in a single family having a high penetrance of early-onset pancreatic ductal adenocarcinoma and pancreatic insufficiency. The goal of this study is to determine if linkage to chromosome 4q exists in our series of well-characterized families with idiopathic familial pancreatic cancer enrolled in the Pancreatic Cancer Genetic Epidemiology Consortium (PACGENE). METHODS: Parametric and nonparametric linkage analyses were performed using 21 microsatellite markers on chromosome 4 on affected individuals with pancreatic cancer from 42 familial pancreatic cancer kindreds. RESULTS: Markov Chain Monte Carlo parametric and nonparametric linkage analyses using SIMWALK2 as well as nonparametric linkage analysis using MERLIN did not provide strong evidence of linkage in this region (LOD < 1.0). Only one family provided a multipoint LOD score of >0.5 adjacent to the reported region. CONCLUSIONS: Our results do not support linkage to the 4q32-34 region in the majority of our familial pancreatic cancer kindreds. However, because multiple pancreatic cancer susceptibility genes are likely to exist, it is possible that a subset of the families in this study may be linked to this region.
Authors: B K Suarez; J Lin; J S Witte; D V Conti; M I Resnick; E A Klein; J K Burmester; D A Vaske; T K Banerjee; W J Catalona Journal: Prostate Date: 2000-10-01 Impact factor: 4.104
Authors: Noriyoshi Fukushima; Norihiro Sato; Takashi Ueki; Christophe Rosty; Kimberly M Walter; Robb E Wilentz; Charles J Yeo; Ralph H Hruban; Michael Goggins Journal: Am J Pathol Date: 2002-05 Impact factor: 4.307
Authors: Julie Earl; Li Yan; Louis J Vitone; Janet Risk; Steve J Kemp; Chris McFaul; John P Neoptolemos; William Greenhalf; Ralf Kress; Mercedes Sina-Frey; Stephan A Hahn; Harald Rieder; Detlef K Bartsch Journal: Cancer Epidemiol Biomarkers Prev Date: 2006-10 Impact factor: 4.254
Authors: Michael A Eberle; Roland Pfützer; Kay L Pogue-Geile; Mary P Bronner; David Crispin; Michael B Kimmey; Richard H Duerr; Leonid Kruglyak; David C Whitcomb; Teresa A Brentnall Journal: Am J Hum Genet Date: 2002-02-27 Impact factor: 11.025
Authors: Alison P Klein; Kieran A Brune; Gloria M Petersen; Michael Goggins; Anne C Tersmette; G Johan A Offerhaus; Constance Griffin; John L Cameron; Charles J Yeo; Scott Kern; Ralph H Hruban Journal: Cancer Res Date: 2004-04-01 Impact factor: 12.701
Authors: Kathleen M Murphy; Kieran A Brune; Constance Griffin; Jennifer E Sollenberger; Gloria M Petersen; Ravi Bansal; Ralph H Hruban; Scott E Kern Journal: Cancer Res Date: 2002-07-01 Impact factor: 12.701
Authors: Marcia Irene Canto; Michael Goggins; Charles J Yeo; Constance Griffin; Jennifer E Axilbund; Kieran Brune; Syed Z Ali; Sanjay Jagannath; Gloria M Petersen; Elliot K Fishman; Steven Piantadosi; Francis M Giardiello; Ralph H Hruban Journal: Clin Gastroenterol Hepatol Date: 2004-07 Impact factor: 11.382
Authors: Stephan A Hahn; Bill Greenhalf; Ian Ellis; Mercedes Sina-Frey; Harald Rieder; Birgit Korte; Berthold Gerdes; Ralf Kress; Andreas Ziegler; John A Raeburn; Donata Campra; Robert Grützmann; Helga Rehder; Matthias Rothmund; Wolff Schmiegel; John P Neoptolemos; Detlef K Bartsch Journal: J Natl Cancer Inst Date: 2003-02-05 Impact factor: 13.506
Authors: Alison P Klein; Michael Borges; Margaret Griffith; Kieran Brune; Seung-Mo Hong; Noriyuki Omura; Ralph H Hruban; Michael Goggins Journal: Cancer Epidemiol Biomarkers Prev Date: 2009-03-31 Impact factor: 4.254